

Abstract of the Disclosure

The invention relates to the use of PP2A/B γ and to the use of a PP2A phosphatase comprising the PP2A/B γ subunit for screening for modulators thereof. The use of these modulators for treating mental disorders such as bipolar disorder, schizophrenia and depression, and drugs comprising these modulators are further disclosed. The invention
5 also discloses biallelic markers located in the gene encoding PP2A/B γ and their use for diagnosing mental disorders.